23 October 2015 - The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic).

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468832.htm